^
Association details:
| Biomarker: | KRAS wild-type |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | VEGF inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Second-line treatment strategies for RAS wild-type colorectal cancer: A systematic review and Network Meta-analysis (NMA)
Published date:
08/14/2023
Excerpt:
A random-effect NMA of phase II/III RCTs was conducted to evaluate IIL treatment for all-RAS wt mCRC, comparing anti-EGFR or anti-VEGF, and chemotherapy (CT)….In KRAS wt patients, PFS was improved with anti-VEGF (HR 0.43) and anti-EGFR (HR 0.63) vs CT. However, anti-VEGF based therapy had the highest likelihood of being ranked as the best treatment in terms of PFS (SUCRA 99.3%) and OS (SUCRA 99.4%).
DOI:
https://doi.org/10.1016/j.dld.2023.07.013
